Multiparametric Cardiac Magnetic Resonance Imaging Detects Altered Myocardial Tissue and Function in Heart Transplantation Recipients Monitored for Cardiac Allograft Vasculopathy.
Coronary angiography
Graft rejection
Heart transplantation
Magnetic resonance imaging
Journal
Journal of cardiovascular imaging
ISSN: 2586-7296
Titre abrégé: J Cardiovasc Imaging
Pays: Korea (South)
ID NLM: 101728106
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
05
01
2022
revised:
26
04
2022
accepted:
02
05
2022
entrez:
24
10
2022
pubmed:
25
10
2022
medline:
25
10
2022
Statut:
ppublish
Résumé
Cardiac allograft vasculopathy (CAV) is a complication beyond the first-year post-heart transplantation (HTx). We aimed to test the utility of cardiac magnetic resonance (CMR) to detect functional/structural changes in HTx recipients with CAV. Seventy-seven prospectively recruited HTx recipients beyond the first-year post-HTx and 18 healthy controls underwent CMR, including cine imaging of ventricular function and T1- and T2-mapping to assess myocardial tissue changes. Data analysis included quantification of global cardiac function and regional T2, T1 and extracellular volume based on the 16-segment model. International Society for Heart and Lung Transplantation criteria was used to adjudicate CAV grade (0-3) based on coronary angiography. The majority of HTx recipients (73%) presented with CAV (1: n = 42, 2/3: n = 14, 0: n = 21). Global and segmental T2 (49.5 ± 3.4 ms vs 50.6 ± 3.4 ms, p < 0.001;16/16 segments) were significantly elevated in CAV-0 compared to controls. When comparing CAV-2/3 to CAV-1, global and segmental T2 were significantly increased (53.6 ± 3.2 ms vs. 50.6 ± 2.9 ms, p < 0.001; 16/16 segments) and left ventricular ejection fraction was significantly decreased (54 ± 9% vs. 59 ± 9%, p < 0.05). No global, structural, or functional differences were seen between CAV-0 and CAV-1. Transplanted hearts display functional and structural alteration compared to native hearts, even in those without evidence of macrovasculopathy (CAV-0). In addition, CMR tissue parameters were sensitive to changes in CAV-1 vs. 2/3 (mild vs. moderate/severe). Further studies are warranted to evaluate the diagnostic value of CMR for the detection and classification of CAV.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiac allograft vasculopathy (CAV) is a complication beyond the first-year post-heart transplantation (HTx). We aimed to test the utility of cardiac magnetic resonance (CMR) to detect functional/structural changes in HTx recipients with CAV.
METHODS
METHODS
Seventy-seven prospectively recruited HTx recipients beyond the first-year post-HTx and 18 healthy controls underwent CMR, including cine imaging of ventricular function and T1- and T2-mapping to assess myocardial tissue changes. Data analysis included quantification of global cardiac function and regional T2, T1 and extracellular volume based on the 16-segment model. International Society for Heart and Lung Transplantation criteria was used to adjudicate CAV grade (0-3) based on coronary angiography.
RESULTS
RESULTS
The majority of HTx recipients (73%) presented with CAV (1: n = 42, 2/3: n = 14, 0: n = 21). Global and segmental T2 (49.5 ± 3.4 ms vs 50.6 ± 3.4 ms, p < 0.001;16/16 segments) were significantly elevated in CAV-0 compared to controls. When comparing CAV-2/3 to CAV-1, global and segmental T2 were significantly increased (53.6 ± 3.2 ms vs. 50.6 ± 2.9 ms, p < 0.001; 16/16 segments) and left ventricular ejection fraction was significantly decreased (54 ± 9% vs. 59 ± 9%, p < 0.05). No global, structural, or functional differences were seen between CAV-0 and CAV-1.
CONCLUSIONS
CONCLUSIONS
Transplanted hearts display functional and structural alteration compared to native hearts, even in those without evidence of macrovasculopathy (CAV-0). In addition, CMR tissue parameters were sensitive to changes in CAV-1 vs. 2/3 (mild vs. moderate/severe). Further studies are warranted to evaluate the diagnostic value of CMR for the detection and classification of CAV.
Identifiants
pubmed: 36280267
pii: 30.263
doi: 10.4250/jcvi.2022.0003
pmc: PMC9592247
doi:
Types de publication
Journal Article
Langues
eng
Pagination
263-275Subventions
Organisme : NIH HHS
ID : R01 HL117888
Pays : United States
Informations de copyright
Copyright © 2022 Korean Society of Echocardiography.
Déclaration de conflit d'intérêts
The authors have no financial conflicts of interest.
Références
Catheter Cardiovasc Interv. 2018 Dec 1;92(7):E527-E536
pubmed: 30265435
J Heart Lung Transplant. 2011 Sep;30(9):1044-50
pubmed: 21640617
J Cardiovasc Magn Reson. 2013 Oct 14;15:92
pubmed: 24124732
J Heart Lung Transplant. 2017 Oct;36(10):1037-1046
pubmed: 28779893
JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 2):1632-1641
pubmed: 30878427
Int J Cardiovasc Imaging. 2020 Mar;36(3):533-542
pubmed: 31724114
J Heart Lung Transplant. 2016 Aug;35(8):1040-1
pubmed: 27318788
Curr Opin Cardiol. 2017 May;32(3):316-325
pubmed: 28212149
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
Am J Surg. 1994 Apr;167(4):375-8
pubmed: 8179080
J Magn Reson. 1999 Mar;137(1):247-52
pubmed: 10053155
Curr Cardiovasc Imaging Rep. 2019;12(1):1
pubmed: 31186826
J Heart Lung Transplant. 2010 Jul;29(7):717-27
pubmed: 20620917
Am J Cardiol. 2009 Nov 15;104(10):1351-6
pubmed: 19892049
JACC Cardiovasc Imaging. 2016 Mar;9(3):255-66
pubmed: 26965729
Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1125-32
pubmed: 24908664
J Heart Lung Transplant. 2010 Aug;29(8):914-56
pubmed: 20643330
Transplantation. 2003 Aug 27;76(4):679-82
pubmed: 12973108
Curr Probl Cardiol. 2022 Aug;47(8):101103
pubmed: 35016989
Echocardiography. 2019 Mar;36(3):528-536
pubmed: 30726558
Cardiovasc Res. 2021 Nov 22;117(13):2624-2638
pubmed: 34343276
Transplantation. 2012 Nov 15;94(9):965-70
pubmed: 23044666
Circulation. 1990 Nov;82(5 Suppl):IV269-75
pubmed: 2225415
J Cardiovasc Magn Reson. 2016 Nov 30;18(1):89
pubmed: 27899132
J Am Coll Cardiol. 2014 Mar 4;63(8):799-808
pubmed: 24355800
Transpl Int. 2018 Jan;31(1):82-91
pubmed: 28865096
Am J Transplant. 2016 Oct;16(10):3007-3015
pubmed: 27140676
Transplantation. 2008 Jun 15;85(11):1580-7
pubmed: 18551063
J Thorac Imaging. 2014 May;29(3):147-54
pubmed: 24576837
Radiology. 1988 Oct;169(1):59-63
pubmed: 3420283
Heart Fail Rev. 2022 Jul;27(4):1235-1246
pubmed: 34383194
J Heart Lung Transplant. 1994 Nov-Dec;13(6):1024-38
pubmed: 7865509
Eur Radiol. 2018 Oct;28(10):4111-4121
pubmed: 29713770
Am Heart J. 2010 Apr;159(4):643-651.e2
pubmed: 20362724
Circulation. 1992 Sep;86(3):756-63
pubmed: 1516187
J Heart Lung Transplant. 2017 May;36(5):567-576
pubmed: 28089194
Diagnostics (Basel). 2021 Dec 11;11(12):
pubmed: 34943575
J Cardiovasc Magn Reson. 2018 Sep 20;20(1):67
pubmed: 30231886
Int J Cardiovasc Imaging. 2018 Dec;34(12):1959-1967
pubmed: 30056496
Am J Transplant. 2009 Nov;9(11):2587-96
pubmed: 19843034
Clin Transplant. 2020 Mar;34(3):e13794
pubmed: 31991002
J Magn Reson Imaging. 2019 Mar;49(3):678-687
pubmed: 30142237
J Heart Lung Transplant. 2016 Oct;35(10):1170-1184
pubmed: 27772669
Magn Reson Med. 2004 Jul;52(1):141-6
pubmed: 15236377
Clin Cardiol. 2015 Dec;38(12):770-6
pubmed: 26289321
JACC Cardiovasc Imaging. 2013 May;6(5):613-23
pubmed: 23680373
J Cardiovasc Magn Reson. 2009 Dec 30;11:56
pubmed: 20042111
Magn Reson Med. 2013 Aug;70(2):517-26
pubmed: 23008092
J Am Heart Assoc. 2016 Nov 1;5(11):
pubmed: 27802930